A recent study that claimed to show the benefits of “transgender” medical procedures on minors was secretly funded by a company that specializes in producing puberty-blocking drugs that are used in such procedures.
As reported by Breitbart, the study, “Sex Assigned at Birth Ratio Among Transgender and Gender Diverse Adolescents in the United States,” was written by researchers Brett Dolotina, Alex Keuroghlian, Dana King, and Jack Turban. Featured prominently by several mainstream media outlets, the study defended such practices as hormone injections, puberty-blockers, or amputating sexual organs.
“The sex assigned at birth ratio of TGD adolescents in the United States does not appear to favor AFAB adolescents and should not be used to argue against the provision of gender-affirming medical care for TGD adolescents,” the study claims, attempting to debunk the “social contagion” theory that transgenderism is more of a social trend rather than an actual medical condition.
However, an investigation by the Daily Caller soon revealed that one of the authors, Turban, had previously been paid at least $15,000 by Arbor Pharmaceuticals; Arbor manufactures the drug Triptudor, which is used for puberty-blocking treatment in developing adolescents.
Turban is set to start a new career as an assistant professor of child psychiatry at the University of California, San Francisco (UCSF), which also has ties to the puberty-blocking industry. A previous report by Breitbart revealed that Stephen Rosenthal, director of UCSF’s Benioff Children’s Hospital Child and Adolescent Gender Center, had been paid nearly $17,000 from both AbbVie and Endo Pharmaceuticals, who also produce puberty-blocking drugs.
Another author of the new study, Brett Dolotina, has had known affiliations with far-left and LGBTQ advocacy groups for years; he previously volunteered for GLBTQ Legal Advocates and Defenders, which also promotes sex-change surgeries and other harmful medical procedures on children.